Company Description
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.
Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate.
The company is headquartered in Cardiff, California.
Country | United States |
Founded | 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 40 |
CEO | Mark Rothera |
Contact Details
Address: 2533 South Coast Highway 101, Suite 210 Cardiff, California 92007 United States | |
Phone | 858 400 8470 |
Website | viracta.com |
Stock Details
Ticker Symbol | VIRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001061027 |
CUSIP Number | 92765F108 |
ISIN Number | US92765F1084 |
Employer ID | 94-3295878 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Mark Andrew Rothera | Chief Executive Officer, President and Director |
Dr. Darrel P. Cohen M.D., Ph.D. | Chief Medical Officer |
Dr. Susan Perrine M.D. | Scientific Founder and Consultant |
Dr. Ronald J. Berenson M.D. | Co-Founder and Consultant |
George Hillman | Co-Founder |
Dr. Thalia Papayannopoulou M.D. | Co-Founder |
Dr. Robert M. Williams Ph.D. | Co-Founder |
Dr. Douglas V. Faller M.D., Ph.D. | Scientific Founder and Chairman of Scientific Advisory Board |
Michael Eric Faerm | Chief Financial Officer |
Dr. Ayman El-Guindy | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 14, 2024 | 10-Q | Quarterly Report |
Aug 14, 2024 | 8-K | Current Report |
Jul 29, 2024 | 8-K | Current Report |
Jun 20, 2024 | 8-K | Current Report |
May 31, 2024 | 8-K | Current Report |
May 14, 2024 | 8-K | Current Report |
May 9, 2024 | 10-Q | Quarterly Report |
May 9, 2024 | 8-K | Current Report |
Apr 26, 2024 | ARS | Filing |
Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |